

Madiha Iqbal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/838592/publications.pdf>

Version: 2024-02-01

39
papers

368
citations

932766

10
h-index

839053

18
g-index

40
all docs

40
docs citations

40
times ranked

633
citing authors

#	ARTICLE	IF	CITATIONS
1	<p>Cytokine Release Syndrome: Current Perspectives</p>. ImmunoTargets and Therapy, 2019, Volume 8, 43-52.	2.7	116
2	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal, 2019, 9, 75.	2.8	43
3	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 76-82.	2.0	26
4	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia, 2022, 36, 856-864.	3.3	26
5	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Current Research in Translational Medicine, 2020, 68, 159-170.	1.2	24
6	Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	19
7	Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. American Journal of Hematology, 2019, 94, E172-E174.	2.0	17
8	Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. Journal of Gastrointestinal Oncology, 2019, 10, 400-406.	0.6	15
9	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1â€ Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 1695-1700.	2.0	14
10	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in WaldenstrÃ¶m Macroglobulinemia: A Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e694-e711.	0.2	13
11	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transplantation and Cellular Therapy, 2021, 27, 167.e1-167.e12.	0.6	8
12	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.6	5
13	First Report of Hereditary Lysozyme Amyloidosis in a South Asian Family. Case Reports in Hematology, 2019, 2019, 1-5.	0.3	4
14	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. Blood, 2020, 136, 33-34.	0.6	4
15	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003â€2018). American Journal of Hematology, 0, , .	2.0	4
16	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 668.e1-668.e6.	0.6	4
17	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 147-152.	0.6	3
18	Efficacy of proteasome inhibitorâ€based maintenance following autologous transplantation in multiple myeloma: A systematic review and metaâ€analysis. European Journal of Haematology, 2021, 106, 40-48.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.2	2
20	Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 65-71.	1.3	2
21	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2
22	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	0.8	2
23	New indications and platforms for CAR T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
24	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
25	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7556-7556.	0.8	2
26	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , 2020, 61, 363-370.	2.5	1
27	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. <i>Blood</i> , 2018, 132, 5873-5873.	0.6	1
28	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
29	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	0.6	1
30	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 95-103.	0.6	0
31	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0
32	Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities. <i>Blood</i> , 2018, 132, 4867-4867.	0.6	0
33	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4869-4869.	0.6	0
34	Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo. <i>Blood</i> , 2018, 132, 5558-5558.	0.6	0
35	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. <i>Blood</i> , 2018, 132, 4764-4764.	0.6	0
36	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. <i>Blood</i> , 2018, 132, 4852-4852.	0.6	0

#	ARTICLE	IF	CITATIONS
37	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). Blood, 2021, 138, 3893-3893.	0.6	0
38	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2020, 136, 42-43.	0.6	0
39	Treatment with anti-spike monoclonal antibodies in allogeneic HCT and CAR T-cell recipients with mild to moderate COVID-19: The Mayo Clinic experience.. Journal of Clinical Oncology, 2022, 40, e19049-e19049.	0.8	0